CIP
LGND icon

Cornerstone Investment Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Cornerstone Investment Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$665K Sell
2,105
-100
-5% -$23.6K 0.02% 73
2026
Q1 		$440K Buy
2,205
+507
+30% +$100K 0.02% 76
2025
Q4 		$321K Buy
1,698
+1
+0.1% +$192 0.01% 98
2025
Q3 		$301K Sell
1,697
-128
-7% -$19K 0.01% 113
2025
Q2 		$207K Buy
+1,825
New +$195K 0.01% 159
2025
Q1 		– Sell
-1,984
Closed -$213K – 233
2024
Q4 		$213K Buy
+1,984
New +$224K 0.01% 183

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cornerstone Investment Partners's LGND Position: Q2 2026 in Review

Cornerstone Investment Partners reduced its Ligand Pharmaceuticals (LGND) stake by 4.5% in Q2 2026, selling an estimated $23.6K and leaving 2,105 shares worth $665K. The position accounts for 0.02% of the portfolio, ranked #73.

Cornerstone Investment Partners first reported a position in LGND in Q4 2024 and has held it in 6 quarters since. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Cornerstone Investment Partners held 2,105 shares of Ligand Pharmaceuticals worth $665K as of Q2 2026.
  • Cornerstone Investment Partners sold 100 Ligand Pharmaceuticals shares in Q2 2026, an estimated $23.6K.
  • Ligand Pharmaceuticals made up 0.02% of Cornerstone Investment Partners's portfolio in Q2 2026, its #73 holding.
  • Cornerstone Investment Partners first reported a position in Ligand Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Cornerstone Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.